{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:00:26Z","timestamp":1771563626304,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with transfusion\u2010dependent thalassaemia (TDT) require chronic, life\u2010sustaining red blood cell transfusions, which contribute to iron overload and associated morbidity and mortality. Luspatercept, an inhibitor of the transforming growth factor\u2010beta pathway, decreases transfusion requirements in a subset of transfusion\u2010dependent \u03b2\u2010thalassaemia patients and is increasingly prescribed in clinical practice. Subsequent to regulatory approvals, several reports have identified the risk of extra\u2010medullary haematopoiesis, which resulted in updated safety labelling. In this report, we present a case of a patient with TDT who developed severe splenomegaly, haemolysis and thrombocytopenia necessitating treatment discontinuation.<\/jats:p>","DOI":"10.1111\/bjh.20131","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T22:52:57Z","timestamp":1746053577000},"page":"1806-1810","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute splenomegaly, haemolysis, and thrombocytopenia following luspatercept initiation in a patient with transfusion\u2010dependent thalassaemia: A case report"],"prefix":"10.1111","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0917-0683","authenticated-orcid":false,"given":"Bianca","family":"Zaidel","sequence":"first","affiliation":[{"name":"Department of Medicine University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Garland","sequence":"additional","affiliation":[{"name":"Red Cell Disorders Program of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Merkeley","sequence":"additional","affiliation":[{"name":"Department of Medicine University of British Columbia  Vancouver British Columbia Canada"},{"name":"Red Cell Disorders Program of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2021838"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002725"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u2010163"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010122561"},{"key":"e_1_2_7_6_1","unstructured":"US Food and Drug Administration.Drug safety\u2010related labeling changes (SrLC) [Internet]. US Food and Drug Administration. 2022 [cited 2024 Mar 21]. Available from:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchdetail.page&DrugNameID=2643"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18470"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010178053"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221134404"},{"key":"e_1_2_7_10_1","unstructured":"TaherAT FarmakisD PorterJB CappelliniMD MusallamKM.Guidelines for the management of transfusion\u2010dependent \u03b2\u2010thalassaemia (TDT) 5th edition [Internet]. Thalassaemia International Federation. 2025 [cited 2025 Mar 3]. Available from:https:\/\/thalassaemia.org.cy\/publications\/tif\u2010publications\/guidelines\u2010for\u2010the\u2010management\u2010of\u2010transfusion\u2010dependent\u2010%CE%B2\u2010thalassaemia\u20105th\u2010edition\u20102025\/"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2048065"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.20131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:23:40Z","timestamp":1760689420000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.20131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/bjh.20131"],"URL":"https:\/\/doi.org\/10.1111\/bjh.20131","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2024-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}